

The nephSAP editorial team and the KSAP editorial board extend their sincere appreciation to the following reviewers. Their efforts and insights help improve the quality of these postgraduate education offerings.

nephSAP Review Panel, Volume 21, Number 1, April 2022

Manohar Bairy, MBBS, MD
Tan Tock Seng Hospital
SINGAPORE

Anip Bansal, MD, FASN
University of Colorado Anschutz Medical Campus
UNITED STATES

Eric M. Gibney, MD
Piedmont Healthcare
UNITED STATES

Kiran M. Goli, MD, FASN
Kidney Care Specialists, LLC
UNITED STATES

Elvira O. Gosmanova, MD, FASN
Albany Medical College
UNITED STATES

Sandra Iragorri, MD
Oregon Health and Science University
UNITED STATES

Insara Jaffer Sathick, MBBS
Memorial Sloan Kettering Cancer Center
UNITED STATES

George Jarad, MD
Washington University School of Medicine
UNITED STATES

Poonum Khalid, II, MBBS
Nishtar Medical University Multan
PAKISTAN

Sana F. Khan, MD
University of Virginia
UNITED STATES

Charbel C. Khoury, MD
Washington University in St Louis
UNITED STATES

Norbert H. Lameire, MD, PhD
Ghent University
BELGIUM

Nicolae Leca, MD, FASN
University of Washington
UNITED STATES

Adi Leiba, MD
Assuta Ashdod University Hospital
ISRAEL

Roy O. Mathew, MD, FASN
Loma Linda VA Health Care System
UNITED STATES

Chanigan Nilubol, MD
MedStar Georgetown University Hospital
UNITED STATES

Arash Rashidi, MD, FASN
University Hospitals Cleveland Medical Center
UNITED STATES

Anand M. Ravindran, MD, MBBS
Toledo Clinic Nephrology
UNITED STATES

Subodh J. Saggi, MD, MPH
SUNY Downstate Medical Center
UNITED STATES

Mohamed A. Sekkarie, MD, MPH
Nephrology and Hypertension Associates
UNITED STATES

Iqbal Hamid Shah, MD, MBBS
King Saud University
SAUDI ARABIA

Amit Sharma, MD, MBBS, FASN
Fortis Hospital
INDIA

Michiko Shimada, MD, PhD, FASN
Hirosaki University
JAPAN

Nicole S. Stankus, MD, MS, FASN
University of Chicago
UNITED STATES

Anna T. Valson, MD
Christian Medical College
INDIA

Suthaharan Vimalendran, MD
Orillia Soldiers Memorial Hospital
CANADA

Eranga Wijewickrama, MD, PhD, FASN
University of Colombo
SRI LANKA

Learning Objectives

1. Review the definition, epidemiology and outcomes of acute kidney injury (AKI).
2. Discuss the pathophysiology of different causes of AKI, including ATN, prerenal, cardiorenal, hepatorenal, as well as glomerular and other interstitial lesions that cause AKI.
3. Examine updates in the prevention and treatment of AKI.

Target Audience:

Physicians, scientists, advanced practitioners, nurses, pharmacists, and other health professionals working and training in the field of nephrology.

Accreditation and AMA Credit Designation Statements



In support of improving patient care, the American Society of Nephrology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The American Society of Nephrology designates this internet activity (enduring material) for a maximum of 10.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to Joint Accreditation for the purpose of granting ABIM MOC credit.

MOC points will be applied to only those ABIM candidates who have enrolled in the MOC program. It is your responsibility to complete the ABIM MOC enrollment process.

Original Release Date

April 2022

CME/MOC Termination Date

March 31, 2024

Examination Available Online

On or before April 15, 2022

Estimated Time for Completion

10 hours

Self-Assessment Examination

- ▶ Answers with explanations are provided with a passing score after the first and/or second attempt.
- ▶ This issue will be archived in May 1, 2024, and answers with explanations will be posted on the ASN website.

Method of Participation

- ▶ Read the entire issue that is supplemented by original articles in the reference lists.
- ▶ Complete the online self-assessment examination.
- ▶ Each participant is allowed **two attempts** to pass the examination (75% correct) for CME and MOC.
- ▶ Upon completion, review your score and incorrect answers and print your certificate.

Activity Evaluation, CME, and MOC

1. Go to the **ASN eLEARNING CENTER** (education.asn-online.org)
2. Select **MY ACTIVITIES** from the left-hand navigation.
3. Select the corresponding issue.
4. Read all information on the Overview screen.
5. Follow the onscreen instructions to:
 - a. Complete the Exam (i.e., post test),
 - b. Complete the Evaluation,
 - c. Claim credit/MOC, and
 - d. Print a Certificate

Your complete ASN Transcript is available on the **ASN eLEARNING CENTER**:

- ▶ Select **TRANSCRIPT** on the left-hand navigation.
- ▶ View course status, credits claimed, or print a certificate for completed learning activities.

System Requirements

Compatible Browser and Software

The nephSAP website (nephsap.org) is formatted for cross-browser functionality and should display correctly in all currently supported web browsers. Individual nephSAP articles are available as dynamic HTML or in Portable Document Format (PDF), which requires Adobe Reader or comparable PDF viewing software.

Monitor Settings

The nephSAP website was designed to be viewed in a 1024 × 768 or higher resolution.

Medium or Combination of Media Used

The media used include content provided online as dynamic HTML or downloadable PDF, in addition to an online evaluation and self-assessment examination.

Technical Support

If you have difficulty viewing any of the pages, please refer to the nephSAP technical support page for possible solutions. If you continue having problems, contact ASN at nephsap@asn-online.org.

ASN Disclosure Policy

It is the policy of American Society of Nephrology (ASN) that all individuals in a position to control the content of ASN's educational activities are expected to disclose all their and their life spouse/partner's financial relationships with "ineligible companies" within the prior 24 months as well as other non-financial interests. ("Ineligible companies" are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients.) Participants should note that the use of products outside US Food and Drug Administration (FDA) approved labeling should be considered experimental and are advised to consult current prescribing information for approval indications.

The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in educational activities, but rather to ensure that these activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. In addition, all faculty were instructed to provide balanced, scientifically rigorous, and evidence-based presentations.

ASN requires all individuals in a position to control content for this activity to complete disclosure forms on the ASN website. Responses are listed below.

Disclosures have been reviewed and assessed by ASN. All relationships with ineligible companies have been identified and all relevant financial relationships have been mitigated.

EDITORS:

Alice M. Sheridan, MD—*Employer(s)*: Brigham and Women's Hospital; No additional relevant financial relationship(s) with ineligible companies to disclose.

Martina M. McGrath, MBCChB, FASN—*Employer(s)*: Brigham and Women's Hospital; VA Boston Medical Center; No additional relevant financial relationship(s) with ineligible companies to disclose.

EDITORIAL AUTHOR:

Paul M. Palevsky, MD, FASN—*Employer(s)*: United States Department of Veterans Affairs, VA Pittsburgh Healthcare System, and University of Pittsburgh; *Consultancy*: Janssen Research & Development, LLC; *Advisory or Leadership Role*: National Kidney Foundation: President, Member, Scientific Advisory Board; Renal Physicians Association: Member, Quality, Safety and Accountability Committee; Quality Insights Renal Network 4: Chair, Medical Review Board; UpToDate: Section Editor, Renal Failure; Journal of Intensive Care Medicine: Member, Editorial Board.

AUTHORS:

Andrew Davenport, MD—*Employer(s)*: Royal Free Hospital London; *Consultancy*: Nipro Corporation, Osaka, Japan consulted on dialyzer designs; *Honoraria*: Fresenius medical company for chairing a session at 2021 EDTA-ERA annual meeting; *Advisory or Leadership Role*: President-International Society for Hemodialysis, European Renal Nutrition (ERN) working group aims to conduct research on the impact of lifestyle, diet, nutrient homeostasis, and protein energy wasting; *Other Interests or Relationships*: DiaLive study (clinicalTrials.gov NCT 03065699)

Sergio Dellepiane, MD, PhD—*Employer(s)*: Icahn School of Medicine at Mount Sinai; No additional relevant financial relationship(s) with ineligible companies to disclose.

Ilya G. Glezerman, MD—*Employer(s)*: Pfizer Inc. (spouse); *Ownership Interest*: Pfizer Inc. (spouse); No additional relevant financial relationship(s) with ineligible companies to disclose.

Victoria Gutgarts, MD—*Employer(s)*: Memorial Sloan Kettering Cancer Center; No additional relevant financial relationship(s) with ineligible companies to disclose.

Leal C. Herlitz, MD—*Employer(s)*: Cleveland Clinic; *Consultancy*: ChemoCentryx; *Advisory or Leadership Role*: ASN Kidney 360 editorial board.

Daphne H. Knicely, MD, FASN—*Employer(s)*: University of Virginia; No additional relevant financial relationship(s) with ineligible companies to disclose.

Dennis G. Moledina, MBBS, PhD, FASN—*Employer(s)*: Yale University School of Medicine; *Ownership Interest*: Predict AIN LLC; *Research Funding*: NIDDK K23DK117065, R01DK12681, UH3DK114866, P30DK079310; *Honoraria*: National Kidney Foundation, Remedy Health Media, British Medical Journal; *Patents or Royalties*: DGM is a coinventor of the pending patent application "Methods and Systems for Diagnosis of Acute Interstitial Nephritis" that is subject to an option for a license agreement with Renalytix AI Inc.

Girish N. Nadkarni, MD, MPH—*Employer(s)*: Icahn School of Medicine at Mount Sinai; *Ownership Interest*: Renalytix, Verici, Doximity, Pensive Health; *Consultancy*: Renalytix, Siemens Healthineers, Qiming Capital, GLG consulting, Daiichi Sankyo, Reata, Variant Bio; *Honoraria*: Daiichi Sankyo; *Patents or Royalties*: Renalytix; *Advisory or Leadership Role*: Renalytix.

Mark D. Okusa, MD, FASN—*Employer(s)*: University of Virginia Health System; *Ownership Interest*: Allstate (ALL), Citigroup (C), Nextera Energy (NEE), Pepsico (PEP), Walmart (WAL), BABA, AIG, BK, BCS, BP, CAH, CRRFY, CI, C, CMCSA, CRH, CVS, ERJ, EMR, ENIC, ENGIY, E, EBKDY, FNMA, FDX, FISV, FLEX, FMX, F, FCX, GE, GD, GEBHY, GSK, GRFS, HAL, HCA, HDELY, HMC, INGR, JSAYI, JPM, KGFHY, LH, MCK, MRK, MU, MHK, OMF, OGN, PFE, PNC, PUBGY, REPLY, RDS B, SNY, SBGSY, STT, SMFG, VIV, TSCDY, TXT, TTE; *Consultancy*: HemoShear; *Research Funding*: AM Pharma/Pfizer; *Patents or Royalties*: University of Virginia Patent Office; *Advisory or Leadership Role*: NIDDK/NIDDK DSMB, AstraZeneca; *Other Interests or Relationships*: John Bower Foundation, Travel.

Mark A. Perazella, MD, FASN—*Employer(s)*: Yale University School of Medicine; *Honoraria*: UpToDate; *Advisory or Leadership Role*: Kidney360 (Deputy Editor), AJKD, Journal of Onco-Nephrology (Co-Editor-in-Chief), *Frontiers in Nephrology*: Onco-Nephrology (Associate Editor), Clinical Nephrology (AKI Series Editor), CJASN, KI, and KI Reports (Editorial Board).

Thiago A. Reis, MD—*Employer(s)*: CDRB-Clinica de Doenças Renais de Brasília; *Consultancy*: Baxter, B.Braun, Life Pharma, Contatti Medical (CytoSorbents), Eurofarma; *Honoraria*: AstraZeneca, Baxter, B.Braun, bioMérieux, Life Pharma, Contatti Medical (CytoSorbents), Eurofarma, Jafron,

Nova Biomedical; *Advisory or Leadership Role*: Baxter, bioMérieux, Life Pharma, Contatti Medical (CytoSorbents), Eurofarma; *Speakers Bureau*: AstraZeneca, Baxter, B.Braun, bioMérieux, Life Pharma, Contatti Medical (CytoSorbents), Eurofarma, Jafron, Nova Biomedical.

Claudio Ronco, MD—*Employer(s)*: University of Padova; *Consultancy*: Asahi, Jafron, Toray, Astute, GE, Baxter, Medtronic, Cytosorbents, OCD, Biomerieux; *Honoraria*: Baxter, Fresenius, Astute, GE, Toray, Estor, Medtronic, Jafron, B.Braun; *Advisory or Leadership Role*: Editor-in-Chief of Blood Purification and Contributions to Nephrology and Cardiorenal Medicine, Associate Editor of Nephrology Dialysis and Transplantation.

Alice M. Sheridan, MD—*Employer(s)*: Brigham and Women's Hospital; *Other Interests or Relationships*: nephSAP Editorial Director; No additional relevant financial relationship(s) with ineligible companies to disclose.

Angela Yee Moon Wang, MD, PhD—*Employer(s)*: Queen Mary Hospital, The University of Hong Kong, Hong Kong; *Advisory or Leadership Role*: Ed Board: JASN, Kidney Int, Clin JASN, Nephrol Dial Transplant, Nephron Clin Practice (Associate Editor), Am J Nephrol, J Nephrol, J Diabetes, J Renal Nutrition, J Geriatr Cardiology, Blood Purification, Biomedicine Hub, EMJ, President of International Soc; *Other Interests or Relationships*: President of International Society of Renal Nutrition and Metabolism, Committee member of ISN-ACT, Member of SONG-HD CVD Outcome Measures Working Group, Member of SONG-PD Working Group, Executive committee member of SONG Initiatives, Council member of ISPD, Deputy Chair of ISN Regional Board, Deputy Chair of ISN Education working group.

Henry H.L. Wu, MBChB—*Employer(s)*: National Health Service, United Kingdom; *Other Interests or Relationships*: Early Career Researcher Member for the International Society of Nephrology Cardio-Renal Toolkit Workgroup.

ASN STAFF: Suzanne P. Armstrong, MA—*Employer(s)*: American Society of Nephrology; No additional relevant financial relationship(s) with ineligible companies to disclose.

Commercial Support

There is no commercial support for this issue.